GLP-1RA therapy increases circulating vascular regenerative cell content in people living with type 2 diabetes
Brady Park, Aishwarya Krishnaraj, Hwee Teoh, Ehab Bakbak, Fallon Dennis, Adrian Quan, David A. Hess, Subodh Verma
Abstract
In this post hoc subanalysis of 92 individuals living with T2D and at high cardiovascular risk, the authors summarize the differences in circulating vascular regenerative (VR) progenitor cell content between those on GLP-1RA therapy, on SGLT2 inhibitor without GLP-1RA therapy, and on neither therapy. Those on GLP-1RA therapy demonstrated greater circulating VR progenitor cell content and reduced proinflammatory granulocyte precursor content. These results offer novel mechanistic insights into the cardiometabolic benefits associated with GLP-1RA therapy.
Topics & Concepts
Progenitor cellMedicineType 2 diabetesInternal medicineDiabetes mellitusStem cellInflammationEndocrinologyBiologyCell biologyAngiogenesis and VEGF in CancerCardiac and Coronary Surgery TechniquesApelin-related biomedical research